IGMS(IGMS)
IGMS
10/6/26
IGM Biosciences (IGMS)
Tuesday
3:51 PM
ThesisConcerns over competitive pressures and potential regulatory delays are overshadowing the positive clinical data emerging from trials.
Revenue Outlook
What Moves the Stock
- 01Progress in clinical trials for lead candidates, particularly IGM-2323 for solid tumors
- 02Partnership announcements or collaborations with larger pharmaceutical firms
- 03Regulatory approvals or advancements in the drug development pipeline
- 04Market sentiment towards biotechnology stocks, particularly in oncology
- 05Research and development collaborations with pharmaceutical companies - 100%
- 06Advancements in antibody engineering technology
- 07Growing demand for targeted cancer therapies
FY2024 Snapshot
- Revenue
- $3M
- Rev. Growth
- +25.8%
- Gross Margin
- -240%
- Op. Margin
- -7786%
- Net Margin
- -7309%
- Net Income
- $-196M
- NI Growth
- +20.5%
- EPS
- $-3.24
- 1Y Return
- -90.7%
IGMS Chart
My Notes
- "Market sentiment is shifting as investors weigh the implications of increased competition in the antibody space."
- Moat: IGM's proprietary IgM platform provides a unique technological advantage, but it faces significant competition from established players.
- growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
- Interest rates can affect the cost of capital for biotech firms, impacting their ability to fund R&D.
- Watch on earnings: Clinical trial results for IGM-2323, Cash runway and operating cash flow, Partnership revenue updates.
One Sentence Summary:
IGM Biosciences: the story is balanced — progress in clinical trials for lead candidates, particularly igm-2323 for solid tumors.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers
